Browse the evidence

Participants collectively lost 6,559 lbs over 12 months with a retention rate of 79%.

Weight loss interventions can be effective in a diverse group of healthy adults.

Weight loss was similar for Healthy Low-Fat and Healthy Low-Carbohydrate diets: -12.1 ± 1.1 lbs vs. -13.8 ± 1.0 lbs.

Both diet types can lead to similar weight loss outcomes.

Within both the Healthy Low-Fat (HLF) and Healthy Low-Carbohydrate (HLC) diet arms, the 12-month decrease in BMI was significantly greater for those in the High Quality/High Adherence subgroups compared to the Low Quality/Low Adherence subgroups.

Practitioners should emphasize the importance of both dietary quality and adherence for effective weight loss.

Improvement in dietary quality and adherence may influence weight loss success among those following low-fat and low-carbohydrate diets.

Encourage clients to improve both the quality of their diet and their adherence to dietary plans for better weight loss outcomes.

The Healthy Weight for Living (HWL) intervention resulted in a mean 6-month weight change of −8.8% for HWL and −8.0% for HWL + meal replacements (MR), both significantly better than controls (p < 0.001).

Implementing the HWL intervention can lead to significant weight loss in workplace settings.

Clinically meaningful weight loss (≥5%) was maintained at 18 months in both intervention groups.

The HWL intervention can lead to sustained weight loss over an extended period.

63.4% of survivors of adolescent and young adult cancer had ≥5% weight reduction after anti-obesity medication initiation.

Practitioners may consider AOMs as a viable option for weight management in this population.

The proportion of survivors with severe obesity decreased from 60% to 35% after anti-obesity medication initiation.

AOMs may effectively reduce severe obesity in this demographic.

Anti-obesity medications are effective for weight reduction in survivors of adolescent and young adult cancer.

AOMs can be considered a treatment option for weight management in AYA cancer survivors.

Exogenous β-hydroxybutyrate (BHB) supplementation significantly reduced fat mass by 2 kg and improved body fat percentage in overweight and obese adults.

Practitioners may consider BHB supplementation as a strategy to enhance fat loss in overweight and obese clients.

Patients treated with GLP-1RAs achieved a mean absolute weight loss of 7.33 kg compared to baseline.

GLP-1RAs can be effective for weight loss in IBD patients.

GLP-1 receptor agonist type drugs can help patients achieve considerable weight loss.

Practitioners can consider GLP-1 RAs as a treatment option for weight loss in obese patients.

Nutritional deficiencies, particularly in vitamins and minerals, necessitate dietary counseling and supplementation for post-weight-loss patients.

Dietary counseling should be integrated into post-weight-loss care.

The use of weight reduction medications as an adjunct therapy alongside dietary, exercise, and behavioral interventions is clearly described in current and future guidelines of the German Obesity Society.

Practitioners should consider weight reduction medications as part of a comprehensive treatment plan.

Liraglutide reduced total body mass and lowered absolute and percent android fat over 18 days.

Liraglutide may be effective for weight loss in individuals with type 2 diabetes.

Bariatric surgery is the most durable and effective treatment for severe obesity.

Clinicians should consider bariatric surgery for patients with severe obesity.

The Atrial Fibrillation Better Care pathway emphasizes lifestyle modifications and weight loss strategies for managing AF in obesity.

Implementing lifestyle changes is essential for managing AF in obese patients.

Tirzepatide significantly reduced body weight, BMI, and waist circumference compared with placebo.

Tirzepatide may be an effective treatment for reducing body weight and improving BMI in Chinese adults.

Ecnoglutide produced mean weight loss of –9.9% (1.2 mg), –13.3% (1.8 mg), and –15.4% (2.4 mg) from baseline at 48 weeks, compared with –0.3% with placebo.

Ecnoglutide is effective for weight loss in Asian populations.

78%–93% of participants achieved ≥5% weight reduction with ecnoglutide.

A significant proportion of users can expect meaningful weight loss.

Weight-reduced patients lost 7.2% total body weight (TBW) versus 10.3% in non-weight-reduced patients (p < 0.001).

Practitioners should consider weight-reduction status when evaluating weight loss outcomes with tirzepatide.

Patients switching from semaglutide due to plateau lost 8.1% TBW versus 2.9% for non-responders (p < 0.001).

Switching from semaglutide may yield different weight loss results based on prior response.

Endoluminal interventions should be combined with a moderately intensive diet and lifestyle program lasting at least 12 months for optimal results.

Practitioners should integrate dietary and lifestyle counseling with endoluminal therapies for better outcomes.

Consuming protein three times a day results in an increase in lean mass of 1.15 kg after 8 weeks of resistance training.

Practitioners can recommend three protein meals per day to support muscle gain.